press releases

► 2023
- January
► 2022
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
► 2021
- December
- November
- October
- September
- July
- June
- May
- April
- February
- January
► 2020
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
► 2019
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
► 2018
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
► 2017
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
► 2016
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
► 2015
- December
- November
- October
- September
- August
- July
- May
- April
- March
- February
- January
► 2014
- December
- November
- October
- September
- August
- July
- June
- May
- April
- February
- January
► 2013
- December
- November
- August
- July
- May
- January
► 2012
- November
- August
- May
- January
► 2011
- December
- November
- October
- August
- April
- March
► 2010
- October
- June
► 2009
- September
► 2008
- November
- April
► 2007
- March

May 13, 2020

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate1 ST. HELIER, Jersey & SHANGHAI–(BUSINESS… Read More

learn more